The publication of this infographic was funded by Castle Biosciences and is intended for US Healthcare Professionals only.
For dermatologists, the critical question isn’t just what a test result says. It’s “What does this result mean for how I manage my patient?” This infographic shows how DecisionDx-Melanoma fits into real clinical practice, translating three actionable risk prediction results into risk-appropriate decisions for patients with cutaneous melanoma.
Read the full piece to see how DecisionDx-Melanoma risk results inform management decisions:
- Manage early-stage patients using the Class Result to guide ongoing surveillance and imaging
- Decide on SLNB referral with the i31-SLNB result’s personalized likelihood of SLN positivity
- Guide node-negative patients with the i31-ROR result, identifying high recurrence risk even after a negative SLNB
- Act on higher- and lower-risk results, from prompting surgical referral to supporting appropriate de-escalation and avoiding unnecessary SLNB
